Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

Core Insights - Cellectis is presenting research data on TALEN®-mediated non-viral transgene insertion and advancements in genetic editing using TALE base editors at the ASGCT annual meeting in May 2025 [1][13] - The company aims to develop life-saving cell and gene therapies through its innovative gene-editing platform [1][14] Group 1: TALEN®-Mediated Non-Viral Transgene Insertion - Cellectis combines TALEN®-mediated gene editing with non-viral delivery methods to enhance cellular and gene therapies, focusing on gene insertion efficacy and cellular health using single-stranded DNA (ssDNA) [3][4] - This approach addresses challenges associated with traditional viral methods, such as manufacturing constraints and potential genomic toxicities [4][10] - The research indicates that TALEN®-mediated gene editing with non-viral templates can achieve high efficiency in gene insertion in T-cells and hematopoietic stem and progenitor cells (HSPCs) [10] Group 2: TALE Base Editors (TALEB) - TALEB technology allows for high-fidelity C-to-T editing of double-stranded DNA without DNA strand nicking, enhancing the precision of gene editing [7][11] - Cellectis has developed methods to characterize TALEB efficiency and assess factors influencing its activity, including target sequence composition [8][11] - The research shows that TALEB can achieve efficient C-to-T conversion while maintaining specificity, with no detectable off-target editing in primary cells [11][12] Group 3: Future Implications - The advancements in TALEN® and TALEB technologies are expected to provide alternative, efficient, and safe therapeutic options for patients with various diseases, including cancer and autoimmune disorders [6][10] - Cellectis' innovative gene-editing tools are positioned to support novel gene therapy applications, enhancing the control and efficiency of gene editing processes [12][13]